Clinical Trial Update: Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for toripalimab as adjuvant therapy after radical resection in hepatocellular carcinoma is in Phase 2 and Phase 3; status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Hepatocellular Carcinoma | Phase 2, Phase 3 | Status: UNKNOWN